Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4550 | leucovorin Wiki | 0.50 |
| drug4267 | Voraxaze Wiki | 0.50 |
| drug3383 | Rituximab Wiki | 0.35 |
Navigate: Correlations HPO
There are 4 clinical trials
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
Description: All serum samples will be tested via MTX immunoassay (measures MTX levels in addition to byproducts) as well as HPLC or mass spectroscopy which will reveal plasma concentrations of MTX and DAMPA separately.
Measure: number of patients that have significant reduction of serum methotrexate levels Time: 1 yearThe aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.
Description: Clinical condition will be measured by lung injuries
Measure: Change in clinical conditions Time: 21 daysDescription: Evaluation of Pneumonia change
Measure: Change of Clinical symptoms - respiratory rate Time: 21 daysDescription: oxygen saturation
Measure: Hypoxia Time: 21 daysDescription: PaO2 / FiO2 ratio
Measure: Changes of blood oxygen Time: 21 daysDescription: C-reactive protein and ferritin
Measure: Inflammatory parameters Time: 21 daysDescription: Time to wean off oxygen invasive ventilatory support
Measure: Evolution of Acute Respiratory Syndrome Time: 21 daysDescription: Time to be discharged from hospital
Measure: Hospital discharge Time: 21 dyasDescription: Time to be discharged from ICU
Measure: ICU discharge Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality Time: 4 monthsThe aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.
Description: Clinical condition will be measured by lung injuries
Measure: Change in clinical conditions Time: 21 daysDescription: Evaluation of Pneumonia change
Measure: Change of Clinical symptoms - respiratory rate Time: 21 daysDescription: oxygen saturation
Measure: Hypoxia Time: 21 daysDescription: PaO2 / FiO2 ratio
Measure: Changes of blood oxygen Time: 21 daysDescription: C-reactive protein and ferritin
Measure: Inflammatory parameters Time: 21 daysDescription: Time to wean off oxygen invasive ventilatory support
Measure: Evolution of Acute Respiratory Syndrome Time: 21 daysDescription: Time to be discharged from hospital
Measure: Hospital discharge Time: 21 dyasDescription: Time to be discharged from ICU
Measure: ICU discharge Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality Time: 4 monthsThe aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.
Description: Clinical condition will be measured by lung injuries
Measure: Change in clinical conditions Time: 21 daysDescription: Evaluation of Pneumonia change
Measure: Change of Clinical symptoms - respiratory rate Time: 21 daysDescription: oxygen saturation
Measure: Hypoxia Time: 21 daysDescription: PaO2 / FiO2 ratio
Measure: Changes of blood oxygen Time: 21 daysDescription: C-reactive protein and ferritin
Measure: Inflammatory parameters Time: 21 daysDescription: Time to wean off oxygen invasive ventilatory support
Measure: Evolution of Acute Respiratory Syndrome Time: 21 daysDescription: Time to be discharged from hospital
Measure: Hospital discharge Time: 21 dyasDescription: Time to be discharged from ICU
Measure: ICU discharge Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality Time: 4 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports